A Dose Escalation and Expansion Study of RO7121661, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Cancer Melanoma Metastatic Melanoma Lung Cancer Non-Small Cell Lung Cancer (NSCLC) Small Cell Lung Cancer Solid Tumors Esophageal Squamous Cell Carcinoma
For the latest version of this information please go to www.forpatients.roche.com